Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

This article describes the public health impact of Alzheimer's disease (AD), including
incidence and prevalence, mortality and morbidity, costs of care, and the overall impact on …

Importance There are limitations in current diagnostic testing approaches for Alzheimer
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) …

In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …

Biomarkers have become an essential component of Alzheimer disease (AD) research and
because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used …

Executive summary Alzheimer's disease (AD) is the leading cause of dementia, and
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …

Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …

Abstract Interpretation of clinical trials comparing different drug regimens for Parkinson's
disease (PD) is complicated by the different dose intensities used: higher doses of levodopa …

This review of Alzheimer's disease assembles a variety of findings relevant to the
mechanism of the disease and ties them together using the current understanding of the …